RxDoctor Payments DataLook up a doctor →

Savannah Sanchez, PA

Physician Assistant · Baton Rouge, LANPI 1598153751

Payments from drug & device makers

$18,931in general payments, 2019–2025

Across 1,241 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Acadia Pharmaceuticals Inc$2K
  • Neurocrine Biosciences, Inc.$2K
  • MDD US Operations, LLC$920
  • UCB, Inc.$917
  • Pfizer$826
  • plus $8K from 37 others

What the payments were for

  • Speaking & faculty fees$630%
  • Food & beverage$18,63998%
  • Education$2291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,931 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$86,392
Medicare patients
453
Services billed
2,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate64$527,594
NuplazidPimavanserin Tartrate48$234,899
RytaryCarbidopa/Levodopa180$202,544
AustedoDeutetrabenazine13$67,465
Nurtec OdtRimegepant Sulfate22$59,587
QuliptaAtogepant39$56,739
Rasagiline Mesylate138$19,550
Aimovig AutoinjectorErenumab-Aooe26$18,630
AzilectRasagiline Mesylate13$14,279
Emgality PenGalcanezumab-Gnlm13$11,130
Carbidopa-LevodopaCarbidopa/Levodopa296$9,640
Rivastigmine72$7,329
Levetiracetam129$6,363
Primidone180$5,382
Memantine Hcl ErMemantine Hcl50$4,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,963$527,59464 claims
Acadia Pharmaceuticals IncNuplazid$2,375$234,89948 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$688$203,567205 claims
Teva Pharmaceuticals USA, Inc.Austedo$800$67,46513 claims
PfizerNurtec Odt$826$59,58722 claims
AbbVieQulipta$3,632$56,73939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →